Isolated Adrenocorticotropic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma

We describe a 58-year-old man with a malignant melanoma metastasis to the liver. After initiation of nivolumab therapy, he developed destructive thyroiditis and subsequently simultaneous isolated adrenocorticotropic hormone (ACTH) deficiency and severe hypercalcemia. Although isolated ACTH deficienc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine research 2018-04, Vol.10 (4), p.358-362
Main Authors: Takebayashi, Kohzo, Ujiie, Atsushi, Kubo, Mio, Furukawa, Sho, Yamauchi, Mototaka, Shinozaki, Hiroyuki, Suzuki, Tatsuhiko, Naruse, Rika, Hara, Kenji, Tsuchiya, Takafumi, Inukai, Toshihiko
Format: Article
Language:English
Subjects:
Case Report
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We describe a 58-year-old man with a malignant melanoma metastasis to the liver. After initiation of nivolumab therapy, he developed destructive thyroiditis and subsequently simultaneous isolated adrenocorticotropic hormone (ACTH) deficiency and severe hypercalcemia. Although isolated ACTH deficiency and hypercalcemia due to nivolumab therapy are both rare occurrences, these conditions can often cause a severe clinical course accompanied by a disturbance of consciousness. Therefore, clinicians should pay attention to these possible side effects of nivolumab if the patients have clinical symptoms, such as fatigue and a disturbance of consciousness.
ISSN:1918-3003
1918-3011
DOI:10.14740/jocmr3257w